Wilate approved for bleeding episodes in von Willebrand disease (VWD)

WILATE (inactivated von Willebrand Factor/Coagulation Factor VIII concentrate [human]) by Octapharma
WILATE (inactivated von Willebrand Factor/Coagulation Factor VIII concentrate [human]) by Octapharma
The FDA has approved wilate (double virus inactivated von Willebrand Factor/Coagulation Factor VIII concentrate [human], from Octapharma USA) for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated. This approval was based on results from four prospective clinical trials that evaluated the efficacy of wilate in the treatment of acute bleeding episodes and prophylaxis in patients with various types of VWD. Wilate was determined to be successful 84–93% of the time when utilized in the treatment in 1,068 bleeding episodes, with results varying dependent on patient type.

Wilate is expected to be available in early 2010.

For more information call (201) 604-1130 or visit www.octapharma.com.